Navigation Links
Medicare Sets Physician Payment Rate for Percutaneous Kidney Cryoablation
Date:11/7/2007

New Clinical CPT Code Created for Minimally Invasive Procedure to Treat

Kidney Tumors

IRVINE, Calif., Nov. 7 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, announced that the Centers for Medicare and Medicaid Services (CMS) have accepted the recommendation received from the American Medical Association's (AMA) Specialty Society Relative Value Update Committee (RUC) and created a clinical reimbursement code and rate for percutaneous renal cryoablation. The new rate will go into effect January 1, 2008.

The new code is CPT 50593 which will be paid an adjusted average in the $440 range and is the first time there is a specific code and reimbursement rate for this procedure. Percutaneous renal cryoablation is a minimally invasive procedure that allows physicians to destroy small tumors in the kidney by inserting a probe directly through the skin and freezing the cancerous tissue.

Endocare Chairman, CEO and President Craig T. Davenport said: "This represents a significant milestone for Endocare and for cryoablation as a cancer therapy. Recent data showing the safety and effectiveness of renal cryoablation have made a positive impression on the American Medical Association Committee that establishes clinical CPT codes. The new renal cryoablation reimbursement rate, paid at a higher rate than other percutaneous ablation modalities, provides patients and their physicians with a powerful new option when choosing a therapy to treat a dangerous disease."

About Endocare

Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company providing minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

Statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties, including, without limitation, the effects of the new CPT code described above. Among the important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q and other filings with the Securities and Exchange Commission. Such risk factors include, but are not limited to, the following items: the Company may incur significant expenses in the future as a result of the Company's obligation to pay legal fees for and otherwise indemnify former officers and former directors in connection with the ongoing investigation and legal proceedings involving them; the Company has a limited operating history with significant losses and losses may continue in the future; the Company may require additional financing to sustain its operations and without it the Company may not be able to continue operations; the sale of the Company's common stock to Fusion Capital may cause dilution, and the sale of the shares of common stock acquired by Fusion Capital or Frazier Healthcare Ventures could cause the price of the Company's common stock to decline; the Company's business may be materially and adversely impacted by the loss of the Company's largest customer or the reduction, delay or cancellation of orders from this customer or if this customer delays payment or fails to make payment; the Company may be required to make state and local tax payments that exceed the Company's settlement estimates; uncertainty relating to third party reimbursement; uncertainty regarding the ability to convince health care professionals and third party payers of the medical and economic benefits of the Company's products; the risk that intense competition and rapid technological and industry change may make it more difficult for the Company to achieve significant market penetration; and uncertainty regarding the ability to secure and protect intellectual property rights relating to the Company's technology. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. The Company undertakes no obligation to revise, or update publicly, any forward- looking statements for any reason.

Investor Contact: Media Contact: For Additional Information:

Matt Clawson Len Hall Craig T. Davenport, CEO

Allen & Caron, Inc. Allen & Caron, Inc. Michael R. Rodriguez, CFO

(949) 474-4300 (949) 474-4300 Endocare, Inc.

matt@allencaron.com len@allencaron.com (949) 450-5400


'/>"/>
SOURCE Endocare, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
2. Texas Supreme Court Rules Against Medicare HMOs in Hospital Reimbursement Fight
3. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
4. Just Completed Studies Reveal Impact of New Medicare Reimbursement Regulations
5. AHCA: Rescinding $2.7 Billion Medicare Cuts Top Issue for Fall Legislative Agenda
6. University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix
7. Medicare Spending Caps Cause Seniors to Stop Meds
8. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
9. Medicare Every Diabetic Counts Project Gears Up for Kick-Off
10. Medicare Cuts to Physicians Will Harm Washington Seniors
11. More than 10,000 Medicare Patients in Montana Could Be Hit by Proposed Cuts to Home Oxygen Therapy; Access to Power Wheelchairs Would Also Decrease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... TransDark is ... transition from one video to the next without having to set a single keyframe ... blasting transitions to enhance your video production. , TransDark features dynamic transitions that momentarily ...
(Date:4/29/2017)... Texas (PRWEB) , ... April 29, 2017 , ... ... to celebrate the profession and recognize the positive impact veterinarians have on animal ... (WVA) and the World Organization for Animal Health (OIE) choose a theme each ...
(Date:4/28/2017)... NY (PRWEB) , ... April 28, 2017 , ... It's ... there are a number of illnesses that are unclear as to whether or not ... their heads. Bronchitis is one of these illnesses. So, FindaTopDoc took a look into ...
(Date:4/28/2017)... ... 28, 2017 , ... Getting enough sleep affects much more than energy – it also has ... without sleep can compromise motor reaction time, which can increase the risk of having a ... the following tips from the NSF to help you sleep better and feel better:, ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The ... board members and officers for 2017-2018. The annual board election process has been in ... a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... PLANO, Texas , April 20, 2017  Vivify ... via mobile devices, has been awarded a very significant ... care via EMRs to continual care via digital health. ... of key intellectual property and further secures Vivify,s position ... Vivify, launched in 2009, was the first company to ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology: